Full-Time

Assistant General Counsel

Employment

Updated on 9/12/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

Compensation Overview

$220.3k - $352.5k/yr

+ Annual Bonus + Potential Discretionary LTI Bonus + Potential Vehicle Use/Mileage Reimbursement + Potential Phone Use Reimbursement

Franklin Lakes, NJ, USA + 1 more

More locations: San Diego, CA, USA

In Person

Bachelor's, JD

Category
Legal (1)
Required Skills
Mergers & Acquisitions (M&A)

Get referred to Becton Dickinson

See people who can refer or advise you

Requirements
  • A Bachelor's Degree in any discipline from a college or university.
  • A Juris Doctor Degree from an accredited American Bar Association law school.
  • A license to practice law in good standing under the bar of a state that enables admission to practice as in-house counsel in California or New Jersey.
  • A minimum of 7-10 years of employment law experience in a major law firm, major corporate legal department, or a combination of both.
  • Significant experience counseling business leaders and Human Resources on complex employment matters.
  • Demonstrated ability to serve as a trusted advisor, balance legal risk with business objectives, and influence decision-making in a fast-paced environment.
  • Demonstrated business acumen and ability to deliver practical, commercially oriented legal advice in support of business objectives.
  • Substantial experience counseling Human Resources and business leaders on complex employment matters in a multi-state environment.
  • Strong business acumen and ability to align legal advice with organizational objectives.
  • Demonstrated ability to establish credibility with senior leaders and influence business decisions through practical, risk-balanced legal advice.
  • Ability to influence outcomes and navigate complex stakeholder environments.
  • Practical, solution-oriented approach to legal counseling and risk management.
  • Strong project management skills.
  • Exceptional organizational skills with ability to manage multiple ongoing matters with appropriate prioritization based on deadline, significance, and client need.
  • Sound decision-making ability and ability to balance legal risks with business strategy.
  • Excellent business and legal judgment.
  • Experience partnering with global business leaders and working effectively in a complex, matrixed organization.
Responsibilities
  • Provide proactive, strategic employment law advice and counseling to Human Resources and business leaders on workforce matters across the United States, including workforce strategy, organizational design, talent management, organizational transformations, workforce planning, restructurings, employee performance and misconduct, hiring and termination practices, leaves of absence, reasonable accommodations, internal investigations, wage and hour compliance, workplace safety and security, labor relations, employment-related mergers and acquisitions, divestitures, and restrictive covenants.
  • Build relationships with business and functional leaders and serve as a key legal partner in strategic decision-making.
  • Provide legal leadership on enterprise initiatives, helping shape strategy, drive implementation, and support organizational effectiveness.
  • Influence key business decisions through commercially focused legal guidance and strategic risk assessment.
  • Develop legal strategies and action plans necessary to achieve business and company operational goals, including addressing the legal implications of identified business objectives.
  • Partner with Human Resources, Finance, Compliance, and business leadership teams to support transformation initiatives, organizational changes, talent strategies, and other key business objectives.
  • Advise on the design, implementation, and compliance of sales incentive compensation plans and other employee incentive programs for sales teams.
  • Draft and review employment-related documents, including corrective action, performance, and termination documentation, employment and separation agreements, and Human Resources policies.
  • Oversee employment litigation, agency matters, and pre-litigation disputes, including case assessment, litigation strategy, settlement considerations, litigation holds, discovery and initial fact gathering, outside counsel management, and budget oversight.
  • Reduce litigation risk through preventive counseling, training, policy development, and practical guidance to business and Human Resources leaders.
  • Advise on and manage government agency investigations, audits, and enforcement matters involving employment-related issues.
  • Manage legal expenses, including projections and budgets.
  • Monitor employment-related laws and regulations, provide updates to Human Resources, and support implementation of best practices and policy changes.
  • Provide training and education on relevant topics as appropriate.
Desired Qualifications
  • Prior in-house experience is strongly preferred.
  • Experience managing wage and hour matters, including wage and hour class and collective actions, is strongly preferred.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
  • Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
  • Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.

What critics are saying

  • FDA classified BD’s intraosseous recall Class I on August 17, 2026.
  • The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
  • Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.

What makes Becton Dickinson unique

  • BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
  • BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
  • BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
Yahoo Finance
Aug 18th, 2026
Wall Street analysts give Becton, Dickinson a 'moderate buy' rating despite 12% earnings decline forecast

Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".

PR Newswire
Aug 17th, 2026
BD names Gary Sorsher chief quality officer as Jeff Silvestri retires after 25 years

BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.

MedTech Dive
Aug 13th, 2026
BD fully enrolls trial of resorbable mesh for hernia prevention.

BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."

Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.